Terms: = Lymphoma AND TOP2A, TOP2, TP2A AND Treatment
11 results:
1. ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Key Genes and Pathways Associated with Hepatosplenic T-Cell lymphoma (HSTCL) by Bioinformatics Analysis.
Du J; Lu G; Xu B; Han XL; Mou WW
Clin Lab; 2021 May; 67(5):. PubMed ID: 33978371
[TBL] [Abstract] [Full Text] [Related]
3. top2a expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract] [Full Text] [Related]
4. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and top2.
Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
[TBL] [Abstract] [Full Text] [Related]
5. A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.
Ajorloo F; Vaezi M; Saadat A; Safaee SR; Gharib B; Ghanei M; Siadat SD; Vaziri F; Fateh A; Pazhouhandeh M; Vaziri B; Moazemi R; Mahboudi F; Rahimi Jamnani F
PLoS One; 2017; 12(9):e0183969. PubMed ID: 28892521
[TBL] [Abstract] [Full Text] [Related]
6. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
[TBL] [Abstract] [Full Text] [Related]
7. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
[TBL] [Abstract] [Full Text] [Related]
8. The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.
Smith KA; Cowell IG; Zhang Y; Sondka Z; Austin CA
Genes Chromosomes Cancer; 2014 Feb; 53(2):117-28. PubMed ID: 24327541
[TBL] [Abstract] [Full Text] [Related]
9. Sensitivity to top2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
Lu H; Hallstrom TC
PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
[TBL] [Abstract] [Full Text] [Related]
10. Expression of p53, Ki-67, E-cadherin, N-cadherin and top2a in triple-negative breast cancer.
Nakagawa M; Bando Y; Nagao T; Morimoto M; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Sasa M; Tangoku A
Anticancer Res; 2011 Jun; 31(6):2389-93. PubMed ID: 21737670
[TBL] [Abstract] [Full Text] [Related]
11. Multilocus association of genetic variants in MLL, CREBBP, EP300, and top2a with childhood acute lymphoblastic leukemia in Hispanics from Texas.
Piwkham D; Gelfond JA; Rerkamnuaychoke B; Pakakasama S; Rebel VI; Pollock BH; Winick NJ; Collier AB; Tomlinson GE; Beuten J
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1204-12. PubMed ID: 21493871
[TBL] [Abstract] [Full Text] [Related]
